Medroxyprogesterone acetate
- Generic Name
- Medroxyprogesterone acetate
- Brand Names
- Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34O4
- CAS Number
- 71-58-9
- Unique Ingredient Identifier
- C2QI4IOI2G
- Background
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosi...
- Indication
Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology. Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis ...
- Associated Conditions
- Abnormal Uterine Bleeding, Amenorrhea, Endometrial Hyperplasia, Endometriosis related pain, Metastatic Renal Cell Carcinoma ( mRCC), Osteoporosis, Pain, Postmenopausal Osteoporosis, Pregnancy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Metastatic Endometrial carcinoma
- Associated Therapies
- Contraception, Estrogen Replacement Therapy, Hormonal Contraception therapy
Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
- Conditions
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2015-06-04
- Target Recruit Count
- 120
- Registration Number
- NCT00044837
- Locations
- 🇺🇸
Barbara Brizz, Rockville, Maryland, United States
Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-02
- Target Recruit Count
- 76
- Registration Number
- NCT00016601
- Locations
- 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Indiana Univ Hosp, Indianapolis, Indiana, United States
Hormonal Birth Control and the Risk of Acquiring HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 6360
- Registration Number
- NCT00006324
- Locations
- 🇺🇸
Amy Lovvorn, Research Triangle Park, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.